reports
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant As...
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch Steven Tahmooressi to lead global marketing efforts for GraftAssure family of assays and future productsBrings 25 years of experience driving new product adoption across geographies in transplantation, oncology and immunology NASHVILLE, Tenn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it has welcomed Steven Tahmooressi to its executive leadership team as the company prepares to launch its first clinical kitted assay in 2026. As Vice ...
Liquidia Corporation to Host R&D Day in New York City on October 28, 2...
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 MORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it will host a Research & Development Day (R&D Day) on Tuesday, October 28, 2025, in New York City which will be webcast from 2:00 p.m. to 4:30 p.m. Eastern Standard Time. The event will feature presentations from Liquidia’s management team alongside three key opinion leaders (KOLs) in the treatment...
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with No...
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancersGraftAssure used to help avoid overtreatment and preserve patient’s immune systemAs transplant care evolves to include novel therapies, the need for ongoing molecular diagnostic monitoring should continue to grow NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasd...
Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 ...
Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting MORRISVILLE, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the company will present two oral presentations at the CHEST 2025 annual meeting on October 19-22, 2025, in Chicago. The company’s two presentations will focus on new data from its ASCENT trial pertaining to both the safety and exploratory efficacy of LIQ861 DPI treprostinil in PH-ILD patients...
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transpl...
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meetingPresenting on GraftAssureIQ at symposium on Thursday, October 9th at the American Society of Histocompatibility and Immunogenetics (ASHI) annual meeting NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced...
BlackRock® Canada Announces Final September Cash Distributions for the...
BlackRock® Canada Announces Final September Cash Distributions for the iShares® Premium Money Market ETF TORONTO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final September 2025 cash distributions for iShares Premium Money Market ETF. Unitholders of record on September 24, 2025 will receive cash distributions payable on September 29, 2025. Details regarding the final “per unit” distribution amounts are as follows: Fund NameFund Ticker Cash Di...
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data D...
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningful and durable antidepressant effects, which are sustained for up to 3 monthsThe second dose of BPL-003 led to further reductions in MADRS scores from baseline, indicating that this regimen has the poten...
atai Life Sciences Awarded Grant from the National Institutes of Healt...
atai Life Sciences Awarded Grant from the National Institutes of Health 5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder NEW YORK and AMSTERDAM, Sept. 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that it has been awarded a multi-year, milestone-driven grant worth up to $11.4 million b...
BlackRock® Canada Announces September Cash Distributions for the iShar...
BlackRock® Canada Announces September Cash Distributions for the iShares® ETFs TORONTO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the September 2025 cash distributions for the iShares ETFs listed on the TSX or Cboe Canada which pay on a monthly or quarterly basis. Unitholders of record of the applicable iShares ETF on September 24, 2025 will receive cash distributions payable in respect of that iShares ETF on September 29, 2025. Details regarding t...
Liquidia Announces Poster Presentations at the Pulmonary Hypertension...
Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium MORRISVILLE, N.C., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present four posters at the Pulmonary Hypertension Professional Association (PHPN) Symposium taking place September 18 – 20, 2025, in Seattle. In a live thematic poster session, Liquidia will highlight new safety and exploratory efficacy da...
Insight Molecular Diagnostics Announces Positive Strategic Update and ...
Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database 5,000-participant, multi-center registry supported by iMDx’s central lab and transplant center partnersNew hospital-based data seeks to further differentiate pending kitted assay that measures biomarker for transplanted organ rejection (dd-cfDNA)Novel registry expected to collect approximately 50,000 samples over three years for organ rejection assay combining both percent and total donor derived cell-free DNA into one scoreRegistry expected to assess utility of “the Berlin protocol” of accelerated...
IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcome...
IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants iMDx’s ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it is actively enrolling patients in its clinical trial to assess GraftAssureDx and that last week, it enrolled the first patient. In addition, now names 10 leading transpl...
atai Life Sciences to Participate in September Investor Conferences
atai Life Sciences to Participate in September Investor Conferences NEW YORK and AMSTERDAM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that its management is scheduled to participate in upcoming September investor conferences. Details of the Company’s participation are as follows: Cantor Global Healthcare Conference 2025 Format: Fireside ChatDate: Friday, September 5th at 8:35 a.m. ETLocation: New...
Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Con...
Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference MORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company’s executive leadership team will be providing an update on the company's business during a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, beginning at 3:45 p.m. ET in Boston. Access to a webcast of the presentation will be available to investors and other interested parties by accessing Liquidia’s website at . An archived, recorded ver...
iMDx to Participate in NYC Investment Conferences September 8 - 11
iMDx to Participate in NYC Investment Conferences September 8 - 11 NASHVILLE, Tenn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced participation in investor conferences hosted by both H.C. Wainwright and Lake Street Capital Markets. Information for each can be found below: Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8 – 9, 2025Location: In-person at the Lotte New York Palace Hotel and virtual Format: Company presentation on Monday, September 8 at 5:00 pm ET, and one-on-one meetingsLink t...
BlackRock® Canada Announces Final August Cash Distributions for the iS...
BlackRock® Canada Announces Final August Cash Distributions for the iShares® Premium Money Market ETF TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final August 2025 cash distributions for iShares Premium Money Market ETF. Unitholders of record on August 26, 2025 will receive cash distributions payable on August 29, 2025. Details regarding the final “per unit” distribution amounts are as follows: Fund NameFund TickerCash Distribution Per...
- Jonathan Moreland
PRGO PERRIGO CO. PLC
POST POST HOLDINGS INC.
MGNX MACROGENICS INC.
MERC MERCER INTERNATIONAL INC.
LOB LIVE OAK BANCSHARES
HTH HILLTOP HOLDINGS INC.
HNRG HALLADOR ENERGY CO.
GLP GLOBAL PARTNERS LP
DIN DINE BRANDS GLOBAL INC.
CE CELANESE CORPORATION
QRHC QUEST RESOURCE HOLDING
HTLD HEARTLAND EXPRESS INC.
RSG REPUBLIC SERVICES INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
BSM BLACK STONE MINERALS LP
NTLA INTELLIA THERAPEUTICS INC.
CYRX CRYOPORT INC.
SD SANDRIDGE ENERGY INC.
ECIA ENCISION INC
UA UNDER ARMOUR
EOLS INC.
CCEL EVOLUS INC
ULBI CRYO-CELL INTERNATIONAL
AVTR ULTRALIFE
EPSN AVANTOR
ASAN INC.
OPCH EPSILON ENERGY LIMITED
MYO ASANA
ATAI OPTION CARE HEALTH INC
PFHC MYOMO
OPAL ATAI LIFE SCIENCES BV
CALC PROFRAC HLDG CORP
ET OPAL FUELS INC
PROP CALCIMEDICA INC.
FIP ENERGY TRANSFER LP
MDRR PRAIRIE OPERATING CO.
ECF FTAI INFRASTRUCTURE INC
LNW MEDALIST DIVERSIFIED REIT INC.
NUGN ELLSWORTH FUND LTD
EFOI LIGHT & WONDER INC.
SST LIVENTO GROUP
STRZ INC.
ENERGY FOCUS INC.
SYSTEM1 INC
STARZ ENTERTAINMENT CORP
BlackRock® Canada Announces August Cash Distributions for the iShares®...
BlackRock® Canada Announces August Cash Distributions for the iShares® ETFs TORONTO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the August 2025 cash distributions for the iShares ETFs listed on the TSX or Cboe Canada which pay on a monthly basis as well as XIU. Unitholders of record of the applicable iShares ETF on August 26, 2025 will receive cash distributions payable in respect of that iShares ETF on August 29, 2025. Details regarding the “per uni...
- Jonathan Moreland
HTH HILLTOP HOLDINGS INC.
CE CELANESE CORPORATION
ASA ASA
ADC AGREE REALTY CORPORATION
HTLD HEARTLAND EXPRESS INC.
PLBC PLUMAS BANCORP
SMRT SMARTSPACE SOFTWARE
EOLS EVOLUS INC
GRNT GRANIT SKOPKE
MYO MYOMO
ATAI ATAI LIFE SCIENCES BV
PFHC PROFRAC HLDG CORP
MSDL MORGAN STANLEY DIRECT LENDING
DMA DESTRA MULTI ALTERNATIVE FUND
atai Life Sciences Reports Second Quarter 2025 Financial Results and R...
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic Reported positive topline data from the core, blinded stage of the Phase 2b clinical trial of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD) BPL-003 met its primary and all key secondary endpoints, and demonstrated rapid, robust and durable antidepressant effects fo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.